FY2028 Earnings Forecast for APLS Issued By HC Wainwright

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities research analysts at HC Wainwright decreased their FY2028 earnings per share estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $2.35 per share for the year, down from their prior estimate of $2.61. HC Wainwright currently has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ FY2029 earnings at $3.84 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08. The business had revenue of $212.50 million during the quarter, compared to analysts’ expectations of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.73) EPS.

APLS has been the subject of several other research reports. Piper Sandler reduced their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th. Royal Bank of Canada lowered their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a report on Monday. JPMorgan Chase & Co. increased their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday. Needham & Company LLC reduced their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Wedbush dropped their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Monday. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.53.

Apellis Pharmaceuticals Stock Up 3.8 %

NASDAQ:APLS opened at $26.00 on Tuesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals has a 1-year low of $23.77 and a 1-year high of $64.33. The company has a 50-day moving average of $29.53 and a 200 day moving average of $31.30. The firm has a market cap of $3.23 billion, a PE ratio of -12.81 and a beta of 0.93.

Insiders Place Their Bets

In other news, CEO Cedric Francois sold 2,824 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total transaction of $83,364.48. Following the sale, the chief executive officer now directly owns 415,695 shares of the company’s stock, valued at $12,271,316.40. The trade was a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $33,351.28. Following the completion of the transaction, the chief accounting officer now directly owns 48,138 shares in the company, valued at approximately $1,464,839.34. The trade was a 2.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,365 shares of company stock valued at $1,810,479. Insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of APLS. Mirae Asset Global Investments Co. Ltd. raised its position in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after buying an additional 781 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Apellis Pharmaceuticals in the third quarter worth $402,000. AlphaCentric Advisors LLC purchased a new position in shares of Apellis Pharmaceuticals during the third quarter worth $1,370,000. Old West Investment Management LLC acquired a new position in Apellis Pharmaceuticals during the third quarter valued at $2,953,000. Finally, Capital Performance Advisors LLP purchased a new stake in Apellis Pharmaceuticals in the third quarter valued at $56,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).